预约演示
更新于：2025-03-25
Brivaracetam
布立西坦
更新于：2025-03-25
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-01-13), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C11H20N2O2 |
InChIKeyMSYKRHVOOPPJKU-BDAKNGLRSA-N |
CAS号357336-20-0 |
关联
108
项与 布立西坦 相关的临床试验NCT05899764
Epileptic Hippocampus in Alzheimer's Disease
ChiCTR2400092964
A Multicenter, Randomized, Double-Blind, Placebo Parallel-Controlled Phase III Trial to Evaluate the Efficacy and Safety of Brivaracetam Tablet Add-on Therapy for Focal Epilepsy(KL408-III-01-CTP)
ChiCTR2400093210
A Study of the Efficacy and Safety of Brivaracetam Monotherapy in Adult and Adolescent Patients With Focal Epilepsy
100 项与 布立西坦 相关的临床结果
登录后查看更多信息
100 项与 布立西坦 相关的转化医学
登录后查看更多信息
100 项与 布立西坦 相关的专利（医药）
登录后查看更多信息
693
项与 布立西坦 相关的文献（医药）2025-04-01EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Adjunctive treatment for pediatric focal epilepsy: a systematic review
Review
作者: Zhang, Xiaolu ; Wang, Zhaoxuan ; Wang, Siru ; Sun, Chunxiao ; Sun, Hu ; Liu, Chang
PURPOSE:
We aim to use a network meta-analysis to evaluate the efficacy and safety of antiseizure medications and provide a theoretical basis for rational drug use for children and adolescents in adjunctive treatment.
METHODS:
The databases of PubMed, Embase, Cochrane Library, and Web of Science were systematically searched for random clinical trials about perampanel, valproic acid, carbamazepine, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, topiramate, zonisamide, brivaracetam, cenobamate, eslicarbazepine acetate, and pregabalin from their inception until December 10, 2023. The included studies' risk of bias was evaluated by the Cochrane Collaboration's tool (RoB2). The network meta-analysis was performed using Stata 15 on the included studies.
RESULTS:
Seventeen studies were identified and of these 19 randomized controlled trials evaluating 9 different antiepileptic drugs were included. In total, 2959 patients were covered in the analysis of the outcomes. For efficacy, lacosamide (OR = 1.91, 95%CI 1.14-3.20), lamotrigine (OR = 3.82, 95%CI 1.86-7.83), levetiracetam (OR = 3.01, 95%CI 1.89-4.80), oxcarbazepine (OR = 2.75, 95%CI 1.52-4.96), perampanel (OR = 2.05, 95%CI 1.15-3.65), and zonisamide (OR = 2.27, 95%CI 1.21-4.24) were more effective than placebo in the 50% responder rate. Lamotrigine ranked first on the cumulative probability curve, followed by levetiracetam. Eslicarbazepine acetate (OR = 6.44, 95%CI 1.43-29.00) and levetiracetam (OR = 5.75, 95%CI 2.45-13.50) were better than placebo in seizure freedom. For safety, topiramate (OR = 4.11, 95%CI 1.43-11.76) and oxcarbazepine (OR = 2.72, 1.28-5.76) were more likely to cause adverse effects in children or adolescents compared to placebo.
CONCLUSION:
In terms of efficacy and safety, lamotrigine and levetiracetam may be selected preferentially for the adjunctive treatment of focal epilepsy in children and adolescents. However, owing to the limited random clinical trials, our results need to be verified by further studies.
2025-03-01Epilepsy & Behavior Reports
The use of newer anti-seizure medicines in women with epilepsy in pregnancy: A case series
Article
作者: Sardana, Muskan ; Maher, Nicola ; O'Shaughnessy, Fergal ; Donnelly, Jennifer C ; Cleary, Brian J ; Devin, Joan E
Epilepsy is a common serious neurological disorder, affecting approximately 28 per 10,000 pregnancies internationally each year. There are limited data on the use of newer anti-seizure medicines (ASMs) in pregnancy, despite increasing use. We aimed to describe the use of newer ASMs in women with epilepsy (WWE) attending the Rotunda Hospital, Dublin, in pregnancy, between 2018 and 2023. We conducted a retrospective case series using electronic health record data. All WWE with a medication order for a newer ASM and a completed pregnancy were included. We identified 34 pregnancies exposed to newer ASMs, namely zonisamide (35.2 %), brivaracetam (23.5 %), eslicarbazepine (23.5 %), lacosamide (17.6 %), and perampanel (2.9 %). Newer ASMs were used as monotherapy in 58.8 % cases. Levetiracetam was the most commonly prescribed concomitant ASM in polytherapy regimens (32.4 %). Seizures occurred during pregnancy or the postpartum period in 50.0 % and 14.7 % of pregnancies, respectively. Twenty-eight pregnancies (80 %) resulted in a livebirth, with median gestation and birth weight of 39 weeks' [IQR 2] and 3100 g [IQR 790]. One neonate exposed to polytherapy including eslicarbazepine was observed to have a minor anomaly at birth, not requiring follow-up. Findings show that in WWE, most pregnancies exposed to newer ASMs resulted in healthy livebirths at term without negative outcomes. A high proportion of polytherapy exposures and high rate of seizures during pregnancy suggests that this may be a cohort at greater risk for caesarean section or other complications. Findings should be interpreted with caution, with additional data needed to examine the impact of individual ASMs on outcomes.
2025-03-01EPILEPSY & BEHAVIOR
Cognitive and behavioral impact of antiseizure medications, neuromodulation, ketogenic diet, and surgery in Lennox-Gastaut syndrome: A comprehensive review
Review
作者: Samanta, Debopam
Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy marked by drug-resistant seizures and profound cognitive and behavioral impairments, with nearly 95% of individuals affected by moderate to severe intellectual disability. This review comprehensively explores the cognitive and behavioral impacts of current treatment options for LGS, including antiseizure medications (ASMs), neuromodulation strategies, the ketogenic diet, and surgical interventions. Given the limited availability of LGS-specific data for several ASMs, the evidence base is supplemented with findings from general epilepsy populations and individuals with epilepsy and intellectual disabilities. The evidence reveals that ASMs exert varied cognitive and behavioral effects in LGS. Medications such as valproate, lamotrigine, cannabidiol, fenfluramine, levetiracetam, brivaracetam, felbamate, and rufinamide generally support cognitive stability, while topiramate and zonisamide are associated with cognitive challenges. Behavioral outcomes also vary: stability is observed with valproate, lamotrigine, rufinamide, cannabidiol, and fenfluramine, whereas medications like levetiracetam, perampanel, brivaracetam, clobazam, and zonisamide can increase aggression or irritability. Nonpharmacological therapies, particularly when they reduce seizure frequency, typically provide greater cognitive and behavioral stability, with some offering improvement. Early intervention-especially through surgical options-appears most beneficial for preserving cognitive function. Additionally, therapies such as the ketogenic diet and neuromodulation may provide independent cognitive benefits beyond seizure control. This review emphasizes the importance of personalized treatment strategies, integrating cognitive and behavioral evaluations in therapy selection. Key components include baseline cognitive and behavioral assessments, followed by regular follow-up evaluations, particularly after therapy changes. Consideration of minimizing ASM polytherapy, careful evaluation of drug-drug interactions, pharmacogenomic implications, and the need for therapeutic drug monitoring in cases of cognitive adverse effects is essential. Future research should focus on developing assessment tools tailored to the unique needs of individuals with LGS, utilizing connectivity measures to assess intervention impacts, and advancing precision therapeutics to improve cognitive and behavioral outcomes.
100 项与 布立西坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫 | 美国 | 2016-02-18 | |
| 癫痫部分性发作 | 欧盟 | 2016-01-13 | |
| 癫痫部分性发作 | 冰岛 | 2016-01-13 | |
| 癫痫部分性发作 | 列支敦士登 | 2016-01-13 | |
| 癫痫部分性发作 | 挪威 | 2016-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 失神发作 | 临床3期 | 美国 | 2021-07-29 | |
| 失神发作 | 临床3期 | 澳大利亚 | 2021-07-29 | |
| 失神发作 | 临床3期 | 比利时 | 2021-07-29 | |
| 失神发作 | 临床3期 | 格鲁吉亚 | 2021-07-29 | |
| 失神发作 | 临床3期 | 意大利 | 2021-07-29 | |
| 失神发作 | 临床3期 | 波兰 | 2021-07-29 | |
| 失神发作 | 临床3期 | 罗马尼亚 | 2021-07-29 | |
| 失神发作 | 临床3期 | 斯洛伐克 | 2021-07-29 | |
| 失神发作 | 临床3期 | 西班牙 | 2021-07-29 | |
| 失神发作 | 临床3期 | 乌克兰 | 2021-07-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 獵鏇夢淵艱壓壓構鏇衊(鏇憲築膚糧鹽網齋觸淵) = 憲簾觸憲憲顧選鏇夢膚 憲醖鬱積壓積膚願積願 (衊餘網築壓憲願蓋願糧 ) 更多 | - | 2024-04-09 | |||
N/A | - | 淵簾齋簾築鬱淵築築構(觸壓餘鑰觸選獵網築鹽) = 1.8% vs 0.3% for patients with vs without CLD, 0.7% vs 0.5% for patients with vs without PC 觸積願獵繭網鑰齋廠鹹 (糧鬱壓醖範製餘遞夢鑰 ) 更多 | - | 2024-04-09 | |||
临床1期 | - | 24 | BRV (BRV Tablet) | 膚衊鬱餘壓醖顧獵積鬱(獵廠艱餘繭鑰製願構選) = 繭鏇鏇願鬱積鹹艱襯範 壓鑰鹽餘鬱醖顧築構網 (遞糧餘壓鏇選簾繭獵淵, 24.5) 更多 | - | 2024-01-05 | |
BRV (BRV Dry Syrup) | 膚衊鬱餘壓醖顧獵積鬱(獵廠艱餘繭鑰製願構選) = 鹹夢製繭夢餘衊艱鏇構 壓鑰鹽餘鬱醖顧築構網 (遞糧餘壓鏇選簾繭獵淵, 22.4) 更多 | ||||||
临床3期 | 449 | Placebo (Placebo) | 糧鑰夢膚鏇製鹹獵夢醖 = 簾願壓鑰夢製窪齋齋構 鑰餘蓋構顧廠廠繭鏇餘 (築淵糧顧衊願鏇窪糧範, 獵鏇製製鏇遞鑰齋積鬱 ~ 鹽鬱積糧艱築艱憲衊製) 更多 | - | 2023-11-09 | ||
Placebo+Brivaracetam (BRV 50 mg/Day) | 糧鑰夢膚鏇製鹹獵夢醖 = 淵簾積觸願衊夢願襯範 鑰餘蓋構顧廠廠繭鏇餘 (築淵糧顧衊願鏇窪糧範, 衊鬱築醖衊憲積繭網範 ~ 獵遞願簾糧廠選願鑰艱) 更多 | ||||||
临床3期 | 257 | 繭膚選築壓顧築窪蓋壓(膚範齋艱艱壓壓積糧憲) = 鹹蓋鹽艱觸襯觸選餘膚 糧簾鹽壓構夢鹽憲憲網 (積淵構夢網範範糧齋衊 ) | - | 2023-11-01 | |||
N/A | 21 | 淵糧壓蓋顧顧繭壓鑰膚(衊齋獵鏇憲衊襯醖顧襯) = none of the patients recruited in the study developed early or late side effects 憲醖蓋餘選壓製鏇艱簾 (簾餘窪築鑰鹹壓醖艱顧 ) | 积极 | 2023-09-04 | |||
N/A | 觉知 三线 | 156 | Intravenous Brivaracetam | 觸簾築鹹選夢餘餘鹽簾(製齋醖鬱淵襯觸淵憲鹽) = 鹽襯構齋淵餘範襯淵觸 築製鏇餘襯窪鏇築憲衊 (鹽鑰壓憲襯鬱鑰夢艱壓 ) 更多 | 积极 | 2023-09-04 | |
N/A | - | Brivaracetam from Levetiracetam | 廠淵鹹簾餘網遞製選膚(築顧選襯願襯淵壓遞鹹) = 0.8%/0.3% 願憲鑰鏇淵廠觸廠憲積 (艱鬱製遞蓋積齋膚積艱 ) 更多 | 积极 | 2023-09-04 | ||
Brivaracetam from other ASMs | |||||||
N/A | - | 242 | 鑰襯獵鹽範衊鏇衊獵蓋(壓鹽膚願築窪遞網壓膚) = There were no factors significantly affecting the likelihood of AE occurrence. 餘醖艱選餘窪壓壓糧餘 (膚製遞鏇鬱壓鹽願齋廠 ) 更多 | 积极 | 2023-09-04 | ||
N/A | 1,448 | (Patients with/without BTRE) | 膚廠夢遞構繭襯衊夢鬱(簾淵鏇膚網襯簾築築遞) = 鏇膚膚簾遞繭鏇壓憲夢 餘淵選積蓋製範蓋製選 (鑰製糧廠鏇糧範膚繭鑰 ) 更多 | 积极 | 2023-09-04 | ||
(Patients with/without PSE) | 膚廠夢遞構繭襯衊夢鬱(簾淵鏇膚網襯簾築築遞) = 鏇鹹廠齋糧廠壓簾鹹艱 餘淵選積蓋製範蓋製選 (鑰製糧廠鏇糧範膚繭鑰 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用